250 results about "Depressed - symptom" patented technology

The present invention relates to a new method of treatment for persons meeting diagnoses for major depressive disorder, or other unipolar (non-bipolar, non-psychotic and non-treatment resistant) depression. The method comprises administering a combination of two categories of drugs, antipsychotics or dopamine system stabilizers, in combination with a newer antidepressant such as a selective serotonin reuptake inhibitor, as initial treatment or as soon as possible. The method targets the prevention of suicide, and provides other benefits including preventing disease progression development of tolerance toward the antidepressants. Another aspect of the invention relates to using the method for alleviating cognitive distortion and related functional impairment or health risks, and / or using the method for smoking cessation or nicotine withdrawal.

Method and apparatus to measure jitter (period-to-period fluctuations in fundamental frequency) among the voices of suicidal, major depressed, and non-suicidal patients to predict near-term suicidal risk.

The invention discloses application of Akkermansia Muciniphila in preparing a drug or health-care product for preventing and treating depression. In the application, in vivo pharmacodynamic research is performed on the effect of the Akkermansia Muciniphila in incidence of the depression and depression resistance; a result shows that abundance of the Akkermansia Muciniphila in an intestinal tract of a patient with the depression is obviously lowered; and a result of an animal experiment shows that abundance of the Akkermansia Muciniphila in an intestinal tract of a mouse with the depression isremarkably lowered. In the application disclosed by the invention, the Akkermansia Muciniphila is transplanted into a model of the mouse with the depression; and tests show that through Akkermansia Muciniphila transplantation, a movement distance of the mouse can be increased, the immobility times of a tail suspension test and a forced swimming test can be shortened, the depression state of the mouse is remarkably relieved, and the Akkermansia Muciniphila shows very good anti-depression curative effect without side effect.

Method and apparatus to measure jitter (period-to-period fluctuations in fundamental frequency) among the voices of suicidal, major depressed, and non-suicidal patients to predict near-term suicidal risk.

Objective discrimination of a disease label of a depressive symptom with respect to an active state of a brain is achieved. One means for solving the problems of the present invention is to provide a discriminating device for assisting in determination of whether a subject has a depressive symptom. The discriminating device includes a storage device for storing information for identifying a classifier generated by classifier generation processing based on a signal obtained by using a brain activity detecting apparatus to measure, in advance and time-sequentially, a signal indicating a brain activity of a plurality of predetermined regions of each brain of a plurality of participants in a resting state, the plurality of participants including healthy individuals and patients with depression. The classifier is generated so as to discriminate a disease label of a depressive symptom based on a weighted sum of a plurality of functional connectivities selected by feature selection as being relevant to the disease label of the depressive symptom through machine learning from among functional connectivities of the plurality of predetermined regions. The discriminating device further includes a processor configured to execute discriminating processing of generating a classification result for the depressive symptom of the subject by using the classifier.

The invention discloses application of vitamin D binding protein as a marker in diagnosis of mental disease depression, and particularly relates to application of a reagent for detecting the content of the vitamin D binding protein in preparation of a reagent for diagnosing the mental disease depression. Differential expression of the vitamin D binding protein in plasma of schizophrenia, bipolar mania, depression and non-mental disease control persons is indicated, and the specificity of the vitamin D binding protein in plasma of depression patients is only improved; the protein is singly usedas a peripheral blood biomarker to detect the content of the protein and is used for diagnosing depression, so that the differential diagnosis accuracy of depression and healthy people or schizophrenia and bipolar mania of other mental diseases can be remarkably improved. Therefore, vitamin D binding protein content detection has high clinical application value in depression diagnosis, and a brand-new way is provided for rapid and effective diagnosis of mental disease depression.

The present invention differentiates objective disease labels for depression symptoms relative to brain activity states. As one means to address the problem to be addressed thereby, the present invention provides a differentiation device that is for helping to determine whether a subject has depression symptoms. The differentiation device comprises a storage device that is for storing informationthat specifies a classifier that has been generated by classifier generation processing from signals obtained by using a brain activity detection device to chronologically premeasure signals that indicate brain activity in a plurality of prescribed regions of the resting brains of each of a plurality of participants that include healthy and depressive patients. The classifier: is generated on thebasis of a weighted sum of a plurality of functional connectivities that, from among functional connectivities between the plurality of prescribed regions, have, by means of machine learning, been selected by feature selection as being related to disease labels for depression symptoms; and is generated to differentiate the disease labels for depression symptoms. The differentiation device also comprises a computing device. Using the classifier, the computing device executes differentiation processing that generates classification results for the depression symptoms of the subject.

The present application relates to the treatment and diagnosis of mood disorders, including bipolar disorder, major depression disorder and schizophrenia. The invention provides novel diagnostic markers and assays, as well as research tools for the development and discovery of agents and compounds which are useful for treating patients who suffer from mental illness.

The invention discloses a polypeptide and an application of the polypeptide in preparation of a drug used for treating depression. The polypeptide is a peptide fragment shown as a sequence 1 or 2 in a sequence table. Experiments prove that once subcutaneous injection drug administration of the polypeptide shown as the sequence 1 or 2 in the sequence table is 100 micrograms / pc, in a rat forced swimming test, compared with a solvent control group and a venlafaxine group, dead time of a rat in forced swimming can be obviously shortened, and in a chronic unpredictability stress test, decrease of sweet water preference value caused by chronic unpredictability stress can be reversed. The polypeptide provided by the invention can immediately take effect after a single drug administration, duration of action is long, and the polypeptide still can treat depression-like behaviours tested on a 36th day after the drug administration. The invention provides a new drug and therapeutic method for preventing and / or treating depression and has a wide application prospect.

The invention discloses a new application of great burdock fruit extract in preparation of drugs or foods for preventing and treating depression. pharmacodynamic tests show that the great burdock fruit extract has good antidepressant effect, prevents secondary memory decline in study caused by the depression and influence of symptoms including anhedonia and the like, and can be applied to preparing the drugs or foods for preventing and treating the depression. The foods are health-caring products or food additives. The drugs can be made into medically acceptable tablets, granules, capsules, compound preparation or the like. An administration observation of 22 cases of depression suffers proves that the effective rate of the great burdock fruit extract can be 90.1%.

The present application provides a method for treating treatment-resistant depression in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of tianeptine, subsequent to a ketamine treatment; also provided is a method of treating suicidal ideation (SI), post-traumatic stress disorder (PTSD), mild cognitive impairment (MCI) or pre-dementia co-morbid with symptoms of depression; and further provided is maintenance therapy for depression remission.